MARIO GUIMARAES PESSOA
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
23 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 23
conferenceObject EFFECTIVENESS OF THE IMPLEMENTATION OF A RE-LINKAGE TO CARE STRATEGY IN PATIENTS WITH HEPATITIS C WHO WERE LOST OF FOLLOW-UP(2021) MENDIZABAL, Manuel; THOMPSON, Marcos Andres; RIDRUEJO, Ezequiel; BALLERGA, Esteban Gonzalez; VELASCO, Jose Antonio Velarde Ruiz; PALAZZO, Ana; MEZZANO, Gabriel; ESPINOSA, Linda Elsa Munoz; PESSOA, Mario; REYES, Eira Cerda; SOZA, Alejandro; RUIZ, Sandro; GOMEZ-ALDANA, Andres Jose; GERONA, Solange; FUSTER, Francisco; ANDERS, Margarita; VALDIVIA, Flor De Maria Beltran; PONIACHIK, Jaime; SCHINONI, Maria Isabel; HERNANDEZ, Nelia; MONTES, Pedro; GIRALA, Marcos; CASTILLO, Lida; CASTILLO-BARRADAS, Mauricio; CHAVEZ, Rocio; CABRERA, Cecilia; TENORIO, Laura; ZEVALLOS, Katherine; GARAVITO, Jorge; BRUTTI, Julia; TAGLE, Martin; NARRO, Graciela Castro; POZO, Emilia Vera; PERAZZO, Rosalia; TORO, Luis Guillermo; VARON, Adriana; FERREIRO, Melina; LAZCANO, Monserrat; MURGA, Maria Dolores; GOMEZ, Fernando; HERNANDEZ, Larissa; MOUTINHO, Bruna Damasio; GANDARA-CALDERON, Julian; VARGAS, Jose Ignacio; SIMIAN, Daniela; SILVA, MarceloconferenceObject YSTRATEGIES TO ELIMINATE HEPATITIS C VIRUS INFECTION IN THE AMERICAS(2023) DIAZ, Luis Antonio; GARCIA, Sergio; AYARES, Gustavo; URIBE, Javier; IDALSOAGA, Francisco; FUENTEALBA, Jose Miguel; FUENTES-LOPEZ, Eduardo; MEDEL, Maria Paz; RAMIREZ-CADIZ, Carolina A.; KHAN, Rayan; LAZO, Mariana; FERRECCIO, Catterina; MENDIZABAL, Manuel; DIRCHWOLF, Melisa Melisa; SALAZAR, Patricia Guerra; OLIVEIRA, Claudia P. M. S.; PESSOA, Mario G.; ALVARES-DA-SILVA, Mario R.; SEBASTIANI, Giada; BRAHMANIA, Mayur; RAMJI, Alnoor; NIAZI, Mina; KO, Hin Hin; FELD, Jordan J.; RESTREPO, Juan Carlos; QUESADA, Wagner Enrique Ramirez; ALFARO, Omar; FERNANDEZ, Marlen Ivon Castellanos; ESTUPINAN, Enrique Carrera; AGUIRRE, Jose Roberto; MALDONADO, Katherine; SANCHEZ, Abel; SANCHEZ, Marco; SR., Teresa Andara; CASTRO-NARRO, Graciela Elia; CHAVEZ-TAPIA, Norberto Carlos; MENDEZ-SANCHEZ, Nahum; ADAMES-ALMENGOR, Enrique; LOMBARDO, Julissa; SR., Marcos Girala; MORAN, Elias; PADILLA-MACHACA, Martin; FERRER, Javier Diaz; TAGLE, Martin; MAINARDI, Vitoria; HERNANDEZ, Nelia; MARTINEZ, Edmundo; ALVARADO-TAPIAS, Edilmar; LEON, Roberto; TALAL, Andrew; THOMAS, Emmanuel; SPRINGER, Sandra; SICILIA, Mauricio Garcia Saenz de; ZHANG, Wei; BAJAJ, Jasmohan S.; TAPPER, Elliot B.; IZZY, Manhal; GISH, Robert G.; ATTAR, Bashar M.; COTTER, Thomas G.; LUCEY, Michael R.; KAMATH, Patrick S.; SINGAL, Ashwani K.; BATALLER, Ramon; MEZZANO, Gabriel; SOZA, Alejandro; LAZARUS, Jeffrey V.; ARRESE, Marco; ARAB, Juan PabloconferenceObject 2-YEAR RESULTS OF TELBIVUDINE (LDT) ROADMAP STUDY VERIFY THE OPTIMAL EFFICACY AND SAFETY RESULTS IN HBEAG POSITIVE CHRONIC HEPATITIS B (CHB) PATIENTS(2012) PIRATVISUTH, T.; KOMOLMIT, P.; TANWANDEE, T.; SUKEEPAISARNJAROEN, W.; CHAN, H. L.; PESSOA, M. G.; FASSIO, E.; ONO-NITA, S.; BESSONE, F.; DARUICH, J.; ZEUZEM, S.; CHEINQUER, H.; DONG, Y.; TRYLESINSKI, A.Background and Aims: The roadmap concept based on Week 24 HBV DNA levels was prospectively validated with 1year results of Roadmap study (A2410) as previously reported. The 2 year results are reported here. Patients and Methods: All patients were HBeAg positive and started LDT monotherapy from baseline and Tenofovir (LDT) was added to patients with detectable (≥300 copies/ml) HBV DNA at 24w until 104w. Results: 105 patients were enrolled and 100 patients were eligible for modified ITT (mITT) analysis (1 patient with baseline M204I mutation, 2 lost follow-up and 2 didn’t follow roadmap concept). At 24w, 55 patients achieved undetectable HBV DNA and 45 patients with detectable HBV DNA added with TDF (73% of the 45 patients with baseline HBV DNA > 9log10 copies/ml). At 104w, 94% had undetectable HBV DNA, 50%/44% HBeAg loss/seroconversion, 7%/4% HBsAg loss/seroconversion. One patient in LDT mono-treated arm had Virologic Breakthrough (VB) at Week 72 and detected M204I mutation; achieved undetectable HBV DNA 8wks after TDF add-on. One LDT mono-treated patient had one time of HBV DNA increase of 1 log10 above nadir (assessment ongoing). Both patients had baseline HBV DNA > 9log10 copies/ml. In the overall safety population, Serious Adverse Events (SAEs) was reported in 6/105 (5.7%) patients and all unrelated to treatment. No case of myopathy/myositis was reported. Overall GFR (by MDRD formula) improvement was +6.4 and +8.6ml/min/1.73m2 in LDT mono and LDT+TDF group respectively. In patients with abnormal baseline GFR (60–90ml/min/1.73m2), GFR improvement at 2yr was +12.0 and +1.5ml/min/1.73m2 in LDT and LDT+TDF respectively. 50% and 40% of patients with abnormal baseline GFR (60–90ml/min/1.73m2) in LDT and LDT+TDF group respectively shifted to normal (>90ml/min/1.73m2) at 2yr. Only 1 patient in TDF add-on group had once creatinine increase to 232 μmol/L at Week 96, and returned to 91 μmol/L within 4 days. Conclusion: Telbivudine roadmap with tenofovir add-on at 24 weeks in patients with detectable HBVDNA improved GFR in both LDT and LDT+TDF treated patients, as well as favorable efficacy and safety profiles.conferenceObject INSULIN RESISTANCE AND HIGH CHOLESTEROL LEVELS ARE ASSOCIATED WITH VITAMIN D DEFICIENCY IN HCV, HIV AND HIV/HCV COINFECTED PATIENTS(2013) GONZALEZ, M. P.; KLAUTAU, G. B.; MAZO, D. F.; NOGUEIRA, R. S.; MENDES-CORREA, M. C. J.; CARRILHO, F. J.; PESSOA, M. G.Background and Aims: Vitamin D plays a role in metabolic syndrome and has also been suggested as an immunomodulator. Lower levels are correlated with severe fibrosis in HCV and HIV/HCV coinfected patients and predict lower response to treatment in those individuals. The aim is to evaluate levels of 25(OH)vitamin D among a population of HCV, HIV and HIV/HCV coinfected patients and describe associated factors. Patients and Methods: We collected 25(OH)vitamin D samples, demographic data, clinical information and laboratory tests including liver function and metabolic assessment of four groups of patients; 1 – HCV monoinfected, 2 – HIV monoinfected, 3 – HIV/HCV coinfected, followed at reference centres of São Paulo-Brazil and 4 – Healthy Volunteers Control Group. Results: 422 patients were included for analysis, (129) Group 1, (118) Group 2, (53) Group 3 and (122) Group 4. Mean levels of Vitamin D were similarly insufficient in all groups (Table 1). Table 1. Mean Levels of Vitamin D in the 4 groups Groups n Mean (ng/mL) St. D. St. E. Median (ng/mL) IQ.D Min (ng/mL) Max (ng/mL) 1– HCV 129 23.4 10.1 0.89 23 13 5 55 2– HIV 118 19.5 9.2 0.85 18 12 4 50 3– HIV/HCV 53 24.1 12.9 1.77 22 15 3 66 4– Control 122 17.1 5.9 0.54 17 8.75 6 32 In an overall analysis, Vitamin D deficiency (serum levels < 20ng/mL) was associated with higher HOMA index (Graph 1 – p=0.02 Fisher test) and total cholesterol levels > 200 (p=0.004 Fisher test). When analyzed by Groups, Vitamin D deficiency was associated with: 1. Higher HOMA levels in HCV patients (Grap h 2 – p=0.004 Fisher test), 2. Use of Efavirenz both in HIV (Graph 3 – p=0.03 OR=6.69 95%CI: 1.17–38.3) and Coinfected Patients (p=0.04 OR=15.0 95%CI: 1.22–184). Conclusion: This study found high prevalence of vitamin D deficiency, even in healthy volunteers. The association between Insulin Resistance (IR) and Vitamin D deficiency has been demonstrated in other populations, but not previously described in HCV patients. This finding is relevant because both IR and Vitamin D deficiency are related to poor treatment outcomes of Interferon-based regimens.conferenceObject Hepatitis A and B Seroprevalence in 1000 Patients with Chronic HCV Infection on a Tertiary Care Center in Brazil(2012) SILVA, Edvaldo F.; MAZO, Daniel F.; OLIVEIRA, Claudia P.; MEDEIROS, Roseane P.; CARRILHO, Flair J.; PESSOA, Mario G.conferenceObject Elimination of hepatitis C in Brazil is cost-saving(2018) BENZAKEN, A.; GIRADE, R.; RAZAVI, H.; SCHMELZER, J.; FERRAZ, M. L.; FERREIRA, P. A.; PESSOA, M. G.; MARTINELLI, A.; CATAPAN, E.; SOUTO, F.; CORREA, M. C. M.conferenceObject The Impact of HEV Infection on the Disease Severity of Patients with Chronic Hepatitis C(2018) ZITELLI, Patricia; GOMES-GOUVEA, Michele; MAZO, Daniel; PINHO, Joo Renato R.; ALVES, Venancio A. F.; TANIGAWA, Ryan Yukimatsu; OLIVEIRA, Claudia S.; CARRILHO, Flair Jose; PESSOA, Mario Guimaraes- Hepatitis C elimination by 2030 is feasible in Brazil: a mathematical modelling approach(2018) BENZAKEN, A.; CATAPAN, E.; GIRADE, R.; RAZAVI, H.; SCHMELZER, J.; PESSOA, M.; FERRAZ, M. L.; FERREIRA, P.; MARTINELLI, A.; CORREA, M. C. M.
conferenceObject Strategies to eliminate hepatitis C virus infection in the Americas(2023) DIAZ, Luis Antonio; GARCIA, Sergio; KHAN, Rayan; AYARES, Gustavo; MONASTERIO, Javier Uribe; IDALSOAGA, Francisco; FUENTES, Eduardo; MEDEL, Maria Paz; RAMIREZ, Carolina; LAZO, Mariana; FERRECCIO, Catterina; MENDIZABAL, Manuel; DIRCHWOLF, Melisa; GUERRA, Patricia; OLIVEIRA, Claudia; PESSOA, Mario; ALVARES-DA-SILVA, Mario; SEBASTIANI, Giada; BRAHMANIA, Mayur; RAMJI, Alnoor; NIAZI, Mina; KO, Hin Hin; FELD, Jordan J.; RESTREPO, Juan Carlos; RAMIREZ, Wagner; ALFARO, Omar; CASTELLANOS-FERNANDEZ, Marlen; CARRERA, Enrique; AGUIRRE, Jose Roberto; CARDONA, Katherine Emilia Maldonado; SANCHEZ, Abel; SANCHEZ, Marco; ANDARA, Maria Teresa; CASTRO-NARRO, Graciela; CHAVEZ-TAPIA, Norberto Carlos; MENDEZ-SANCHEZ, Nahum; ADAMES, Enrique; LOMBARDO, Julissa; GIRALA, Marcos; MORAN, Elias; PADILLA, P. Martin; DIAZ-FERRER, Javier; TAGLE, Martin; MAINARDI, Victoria; HERNANDEZ, Nelia; MARTINEZ, Edmundo; ALVARADO-TAPIAS, Edilmar; ROBERT, Leon; HERNANDEZ-TEJERO, Maria; SICILIA, Mauricio Garcia Saenz De; ZHANG, Wei; BAJAJ, Jasmohan S.; TAPPER, Elliot; IZZY, Manhal; GISH, Robert G.; ATTAR, Bashar; COTTER, Thomas; KAMATH, Patrick S.; SINGAL, Ashwani; BATALLER, Ramon; MEZZANO, Gabriel; SOZA, Alejandro; LAZARUS, Jeffrey; ARRESE, Marco; ARAB, Juan PabloconferenceObject EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR IN TREATMENT-NAIVE ADULTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPES 1-6 IN BRAZIL(2019) PERIBANEZ-GONZALEZ, Mario; CHEINQUER, Hugo; RODRIGUES, Lino; LIMA, Maria Patelli J. S.; ALVARES-DA-SILVA, Mario Reis; MADRUGA, Jose; PARISE, Edison; PESSOA, Mario Guimaraes; FURTADO, Juvencio; VILLANOVA, Marcia G.; FERREIRA, Adalgisa; MAZZOLENI, Felipe; NASCIMENTO, Ecio; LU, Wenjing; SCHNELL, Gretja; BURROUGHS, Margaret; REUTER, Tania
- «
- 1 (current)
- 2
- 3
- »